Dr. Roy S. Chuck Receives Publication Approval for
Amniotic Membrane Immunosuppressive Research
COSTA MESA, California – 30 October 2008 – Roy S. Chuck, M.D. Ph.D. (IOP Inc. Medical Director) has received publication approval for his research manuscript detailing the immunosuppressive properties of the AmbioDry2 Amniotic Membrane technology.
“Immunosuppressive Property of Dried Human Amniotic Membrane” has been approved for publication in Ophthalmic Research.
This research was initially abstracted at the Association of Research in Vision and Ophthalmology (ARVO) meeting in 2007.
The results detail the significant immunosuppressive properties of dehydrated amniotic membrane using an allo-reactive splenocyte proliferation assay.
The study shows that the devitalized, dry preparation of human amniotic membrane maintained its immunosuppressive property and that this feature is potentiated by the preservation of the intact amniotic epithelium. The research concluded that both the amniotic membrane epithelium and the stroma appear critical to achieving optimal immunosuppression.
“Positive immunosuppression represents a critical function of amniotic membrane”, states Erich Ziegler, Vice President. “Dr. Chuck’s compelling research confirms the critical immunosuppressive function of our dehydrated membranes.”
Roy S. Chuck M.D., Ph.D. is The Tom Clancy Professor of Ophthalmology and Director of Refractive Surgery at the Wilmer Eye Institute. A cornea specialist, Dr. Chuck has expertise in the field of laser techniques for refractive eye problems and has published, patented and lectured extensively throughout his career. Dr. Chuck also has a strong research interest in ocular surface corneal transplantation and sight restoration.
Dr. Chuck, a UC Berkeley trained engineer, graduated from the Columbia University College of Physicians and Surgeons where he received his M.D., Ph.D. degree. He completed his fellowship training in Cornea and Refractive Surgery at the Doheny Eye Institute of the University of Southern California. Prior to joining Johns Hopkins University, Dr. Chuck served on the faculties of Ophthalmology and Engineering at Washington University, University of Southern California and University of California, Irvine.
Founded in 1988, IOP, Inc. develops and commercializes specialized, leading-edge surgical technologies for eye surgery. IOP’s purpose is to develop surgical solutions that improve the quality of life for patients, elevate the performance and productivity of eye care professionals, and lower costs to the provider.
IOP currently holds leadership positions with surgical devices for oculoplastic surgeries and bio-implant technologies for cornea, anterior and oculoplastic surgeries.